Litigation Details for NOVARTIS PHARMACEUTICALS CORPORATION v. MACLEODS PHARMACEUTICALS LTD. (D.N.J. 2019)
✉ Email this page to a colleague
NOVARTIS PHARMACEUTICALS CORPORATION v. MACLEODS PHARMACEUTICALS LTD. (D.N.J. 2019)
| Docket | ⤷ Try a Trial | Date Filed | 2019-10-25 |
| Court | District Court, D. New Jersey | Date Terminated | 2019-11-18 |
| Cause | 35:271 Patent Infringement | Assigned To | Mitchell Goldberg (EDPA) |
| Jury Demand | None | Referred To | Douglas Arpert |
| Patents | 8,101,659; 8,877,938; 9,388,134 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in NOVARTIS PHARMACEUTICALS CORPORATION v. MACLEODS PHARMACEUTICALS LTD.
The small molecule drug covered by the patents cited in this case is ⤷ Try a Trial .
Details for NOVARTIS PHARMACEUTICALS CORPORATION v. MACLEODS PHARMACEUTICALS LTD. (D.N.J. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2019-10-25 | 1 | Complaint | expiration of U.S. Patents Nos. 8,101,659 (the “’659 patent”), 8,877,938 (the “’938 patent”), and 9,388,134… THE PATENTS-IN-SUIT AND ENTRESTO® 21. Novartis is the owner of the ’659 patent, titled…copy of the ’659 patent is attached hereto as Exhibit A. 22. The ’659 patent claims, inter alia…copy of the ’938 patent is attached hereto as Exhibit B. 24. The ’938 patent claims, inter alia… ’134 patents in connection with ENTRESTO®. INFRINGEMENT OF THE PATENTS-IN-SUIT | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
